In other words, our data suggested that the KRAS mutation is associated with the greater magnitude of the differential expression of the major pathways that are altered the most (especially the up-regulated pathways) in CRC and perhaps indicate more pronounced genomic dysregulation. The gene discussed is KRAS; the disease is colorectal carcinoma.